KalVista Pharmaceuticals (KALV) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for KalVista Pharmaceuticals (NASDAQ: KALV):

• 4/5/2026 – KalVista Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/28/2026 – KalVista Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/26/2026 – KalVista Pharmaceuticals had its price target raised by Stifel Nicolaus from $39.00 to $42.00. They now have a “buy” rating on the stock.
• 3/26/2026 – KalVista Pharmaceuticals had its price target lowered by Citizens Jmp from $29.00 to $28.00. They now have a “market outperform” rating on the stock.
• 3/25/2026 – KalVista Pharmaceuticals had its price target raised by Needham & Company LLC from $35.00 to $36.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the sale, the insider owned 138,983 shares in the company, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $16.08, for a total value of $107,623.44. Following the completion of the sale, the chief executive officer owned 451,815 shares in the company, valued at approximately $7,265,185.20. This represents a 1.46% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 248,009 shares of company stock worth $4,213,467. Corporate insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.